Travassos, ATeixeira, SFerreira, PRegadas, ITravassos, ASEsperancinha, FPrieto, IPires, Gvan Velze, RValido, AMachado, MC2013-01-102013-01-102007Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):233-71938-2375http://hdl.handle.net/10400.10/852The anatomic response to intravitreal bevacizumab injection in three patients with aggressive, posterior retinopathy of prematurity is described. In all cases, the worse eye was treated with a single intravitreal injection of 0.75 mg of bevacizumab as monotherapy or complementary to laser therapy. In 24 hours, all injected eyes showed regression of the tunica vasculosa lentis and iris vessel engorgement and disappearance of iris rigidity. In addition, plus disease and retinal proliferation began to regress. None of the eyes required additional treatment. Follow-up of up to 10 months showed good anatomic outcomes and no evidence of local or systemic adverse events.engRetinopathy of prematurityIntravitreal bevacizumabNewbornjournal article